Dose-related immunomodulatory effects of recombinant TRAIL in the tumor immune microenvironment.
Immunoregulation
TRAIL
Tumor-associated macrophage
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
16
06
2023
accepted:
10
08
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
In addition to specifically inducing tumor cell apoptosis, recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has also been reported to influence the cancer immune microenvironment; however, its underlying effects and mechanisms remain unclear. Investigating the immunomodulatory effects and mechanisms of recombinant TRAIL in the tumor microenvironment (TME) may provide an important perspective and facilitate the exploration of novel TRAIL strategies for tumor therapy. Immunocompetent mice with different tumors were treated with three doses of recombinant TRAIL, and then the tumors were collected for immunological detection and mechanistic investigation. Methodological approaches include flow cytometry analysis and single-cell sequencing. In an immunocompetent mouse model, recombinant soluble mouse TRAIL (smTRAIL) had dose-related immunomodulatory effects. The optimal dose of smTRAIL (2 mg/kg) activated innate immune cells and CD8 Our results highlight the immunomodulatory role of recombinant TRAIL and suggest promising therapeutic strategies for clinical application.
Sections du résumé
BACKGROUND
BACKGROUND
In addition to specifically inducing tumor cell apoptosis, recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has also been reported to influence the cancer immune microenvironment; however, its underlying effects and mechanisms remain unclear. Investigating the immunomodulatory effects and mechanisms of recombinant TRAIL in the tumor microenvironment (TME) may provide an important perspective and facilitate the exploration of novel TRAIL strategies for tumor therapy.
METHODS
METHODS
Immunocompetent mice with different tumors were treated with three doses of recombinant TRAIL, and then the tumors were collected for immunological detection and mechanistic investigation. Methodological approaches include flow cytometry analysis and single-cell sequencing.
RESULTS
RESULTS
In an immunocompetent mouse model, recombinant soluble mouse TRAIL (smTRAIL) had dose-related immunomodulatory effects. The optimal dose of smTRAIL (2 mg/kg) activated innate immune cells and CD8
CONCLUSION
CONCLUSIONS
Our results highlight the immunomodulatory role of recombinant TRAIL and suggest promising therapeutic strategies for clinical application.
Identifiants
pubmed: 37605148
doi: 10.1186/s13046-023-02795-x
pii: 10.1186/s13046-023-02795-x
pmc: PMC10464183
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
216Subventions
Organisme : National Natural Science Foundation of China
ID : 32071466
Organisme : Jilin University Science and Technology Innovative Research Team
ID : 2017TD-05
Organisme : the "Medicine + X" Interdisciplinary Innovation Team of Norman Bethune Health Science Center of Jilin University
ID : 2022JBGS05
Informations de copyright
© 2023. Italian National Cancer Institute ‘Regina Elena’.
Références
Front Immunol. 2020 Aug 04;11:1731
pubmed: 32849616
J Cell Biochem. 2018 Mar;119(3):2951-2963
pubmed: 29131381
Pancreas. 2016 Mar;45(3):401-8
pubmed: 26390425
Biomed Res Int. 2020 Nov 27;2020:7425397
pubmed: 33313317
Acta Biomater. 2022 Apr 15;143:392-405
pubmed: 35259519
Crit Rev Oncol Hematol. 2019 Nov;143:81-94
pubmed: 31561055
J Mol Cell Cardiol. 2018 Jun;119:51-63
pubmed: 29680681
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Front Immunol. 2015 Nov 23;6:597
pubmed: 26635811
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
EMBO J. 2010 Dec 15;29(24):4223-36
pubmed: 21045807
Cancer Lett. 2022 Jun 1;535:215661
pubmed: 35325845
Immunity. 2022 Jun 14;55(6):1118-1134.e8
pubmed: 35447093
J Biol Chem. 2006 May 19;281(20):13964-71
pubmed: 16547002
J Clin Oncol. 2010 Jun 10;28(17):2839-46
pubmed: 20458040
Invest New Drugs. 2014 Feb;32(1):135-44
pubmed: 23589214
Cancer Res. 2010 Mar 15;70(6):2235-44
pubmed: 20215499
Cell. 2022 May 12;185(10):1694-1708.e19
pubmed: 35447074
Trends Cancer. 2022 Jul;8(7):517-526
pubmed: 35288093
Cell. 2020 Oct 15;183(2):377-394.e21
pubmed: 32976798
Protein Pept Lett. 2022;29(12):1072-1081
pubmed: 36098412
Methods Mol Biol. 2019;1986:255-266
pubmed: 31115893
J Immunol. 2010 Dec 15;185(12):7174-9
pubmed: 21068408
Trends Mol Med. 2013 Nov;19(11):685-94
pubmed: 24076237
Cancer Biol Ther. 2012 Oct;13(12):1143-51
pubmed: 22892844
J Am Soc Nephrol. 2019 May;30(5):767-781
pubmed: 30948627
Cancer Immunol Res. 2019 Feb;7(2):292-305
pubmed: 30459152
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Cell Metab. 2022 Nov 1;34(11):1843-1859.e11
pubmed: 36103895
Mol Carcinog. 2023 Feb;62(2):135-144
pubmed: 36239572
Mol Cell. 2017 Feb 16;65(4):730-742.e5
pubmed: 28212753
Cell. 2019 Oct 31;179(4):829-845.e20
pubmed: 31675496
Cancer Immunol Immunother. 2013 Apr;62(4):653-63
pubmed: 23143747
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Immunity. 2018 Nov 20;49(5):971-986.e5
pubmed: 30413361
Nat Commun. 2018 Feb 28;9(1):873
pubmed: 29491374
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
J Clin Invest. 1999 Jul;104(2):155-62
pubmed: 10411544
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
J Clin Invest. 2014 Jun;124(6):2626-39
pubmed: 24789911
Cell Mol Immunol. 2020 Aug;17(8):807-821
pubmed: 32612154
Bioinformatics. 2021 Aug 25;37(16):2485-2487
pubmed: 33459785
J Leukoc Biol. 2019 Aug;106(2):345-358
pubmed: 30576000
J Leukoc Biol. 2015 Feb;97(2):327-39
pubmed: 25420919
J Exp Med. 1999 Oct 18;190(8):1155-64
pubmed: 10523613
Target Oncol. 2015 Mar;10(1):65-76
pubmed: 24816908
Br J Cancer. 2010 Feb 2;102(3):506-12
pubmed: 20068564
Nature. 2019 Feb;566(7745):496-502
pubmed: 30787437
Mol Med Rep. 2020 Sep;22(3):2227-2234
pubmed: 32705194
Hepatology. 2012 Dec;56(6):2242-54
pubmed: 22711685
J Immunol. 2001 May 1;166(9):5407-15
pubmed: 11313377
Nat Rev Cancer. 2017 May 24;17(6):352-366
pubmed: 28536452
Oncoimmunology. 2016 Feb 18;5(4):e1118599
pubmed: 27141404
Nat Med. 2001 Jan;7(1):94-100
pubmed: 11135622